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Abstract
Background: Axl, together with Tyro3 and Mer, constitute the TAM family of receptor tyrosine kinases. In the
nervous system, Axl and its ligand Growth-arrest-specific protein 6 (Gas6) are expressed on multiple cell types. Axl
functions in dampening the immune response, regulating cytokine secretion, clearing apoptotic cells and debris,
and maintaining cell survival. Axl is upregulated in various disease states, such as in the cuprizone toxicity-induced
model of demyelination and in multiple sclerosis (MS) lesions, suggesting that it plays a role in disease
pathogenesis. To test for this, we studied the susceptibility of Axl-/- mice to experimental autoimmune
encephalomyelitis (EAE), an animal model for multiple sclerosis.
Methods: WT and Axl-/- mice were immunized with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide
emulsified in complete Freund’s adjuvant and injected with pertussis toxin on day 0 and day 2. Mice were
monitored daily for clinical signs of disease and analyzed for pathology during the acute phase of disease.
Immunological responses were monitored by flow cytometry, cytokine analysis and proliferation assays.
Results: Axl-/- mice had a significantly more severe acute phase of EAE than WT mice. Axl-/- mice had more spinal
cord lesions with larger inflammatory cuffs, more demyelination, and more axonal damage than WT mice during EAE.
Strikingly, lesions in Axl-/- mice had more intense Oil-Red-O staining indicative of inefficient clearance of myelin debris.
Fewer activated microglia/macrophages (Iba1+) were found in and/or surrounding lesions in Axl-/- mice relative to WT
mice. In contrast, no significant differences were noted in immune cell responses between naïve and sensitized animals.
Conclusions: These data show that Axl alleviates EAE disease progression and suggests that in EAE Axl functions
in the recruitment of microglia/macrophages and in the clearance of debris following demyelination. In addition,
these data provide further support that administration of the Axl ligand Gas6 could be therapeutic for immune-
mediated demyelinating diseases.
Background
Axl, a member of the TAM family of receptor tyrosine
kinases, has been shown to function in dampening the
immune response, regulating cytokine secretion, clearing
apoptotic cells and debris, and maintaining cell survival
[1-5]. In the nervous system, Axl is widely expressed on
microglia, oligodendrocytes, and neurons [4,6-9], and its
ligand Growth-arrest-specific protein 6 (Gas6) is
expressed on neurons, endothelial cells, astrocytes, and
in the CSF [5,10-13]. Although Axl and Gas6 are highly
expressed during development, Axl is expressed at low
levels in the adult central nervous system (CNS), but is
upregulated in disease states, such as in the cuprizone
toxicity-induced model of demyelination and in multiple
sclerosis (MS) lesions [5,11,14,15].* Correspondence: bridget.shafit-zagardo@einstein.yu.edu1Department of Pathology, Albert Einstein College of Medicine, 1300 Morris
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In vitro, Axl signaling can reduce expression of the
pro-inflammatory cytokine TNFa by upregulating
TWIST, resulting in TWIST binding the E-box of
TNFa, thereby blocking NFB-dependent transcription
of TNFa [16,17]. Several cytokines and chemokines
including TNFa, and the potent immune cell chemoat-
tractant chemokines MCP1 (CCL2) and RANTES
(CCL5) are upregulated in EAE and MS lesions, and
contribute to inflammation and demyelination [18-24].
It is well established that inflammation in the CNS
can block remyelination but clearance of debris by pha-
gocytosis can allow for efficient remyelination (for
review see [25]). Microglia, the resident CNS immune
cells of monocyte lineage, are capable of phagocytosis,
as well as secreting trophic factors that help repair
damage [26-28]. Clearance of apoptotic cells and debris
is a critical pathologic response to inflammation. If
inflammation is left unchecked it can lead to tissue
necrosis and further apoptosis and inflammation. Under
pathologic situations, microglia become activated,
migrate to the site of injury, surround damaged and
dead cells, and clear tissue debris from the area [29].
Axl signaling has a role in phagocytosis; in vitro studies
have shown that deletion of Axl reduced phagocytosis
by fifty percent [30]. Thus, upregulation of Axl in MS
lesions may reflect an attempt to protect resident CNS
cells from apoptosis, to dampen inappropriate activation
of the immune response, and to aid in clearing myelin
debris [5].
In this study, we sought to characterize the role of Axl
in the CNS following MOG35-55-induced EAE, an auto-
immune disease of the CNS that shares several clinical
and pathologic features with MS, including breakdown
of the blood brain barrier (BBB), perivascular inflamma-
tion, demyelination, and axonal degeneration. We stu-
died the acute phase of disease in EAE-induced WT and
Axl-/- mice. We speculated that Axl is important in
minimizing an immune-mediated CNS insult by dam-
pening the inflammatory response, modulating microglia




Axl-/- and Tyro3-/- mice were obtained from Dr. Greg
Lemke at the Salk Institute and further backcrossed
more than six generations onto C57/Bl6J mice (Jackson
ImmunoResearch Laboratories, Bar Harbor, ME) in our
select pathogen-free barrier facility. C57/Bl6J WT litter-
mates were used as controls. All experiments were per-
formed with age and sex-matched mice at 8 weeks of
age. All protocols followed internationally recognized
guidelines and were approved by the Animal Care and
Use Committee at the Albert Einstein College of
Medicine, Protocol Number 20080308; NIH OLAW/
NIH Assurance number is A3312-01.
MOG-induced EAE
Mice were immunized with MOG peptide35-55 (3 mg/ml;
Celtek Bioscience, Franklin, TN) emulsified in an equal
volume of CFA composed of mycobacterium tuberculosis
(10 mg/ml; Difco Laboratories, Detroit, MI) in incom-
plete Freund’s adjuvant (Difco Laboratories). Mice were
anaesthetized with isoflurane and 100 μl of emulsion was
injected subcutaneously on each flank (200 μl total/
mouse) on day 0. In addition, 200 μl of pertussis toxin
(2.5 μg/ml; List Biological Laboratories, Campbell, CA)
was injected into the tail vein on days 0 and 2. In our col-
ony, this regimen produced a milder form of EAE than
has been reported in the literature [31]. Mice were moni-
tored and graded daily for clinical signs of disease as fol-
lows: 0, no disease; 1, limp tail; 2, limp tail and hind limb
weakness; 3, hind limb paralysis; 4, hind limb and front
limb paralysis; 5, moribund. Mice that were considered
borderline between scores were given a half score; 0.5,
1.5, 2.5, 3.5. Data analyses shown in all figures were per-
formed during the acute phase of disease, days 14-19.
Spinal cord dissection and tissue preparation
Mice were anaesthetized with ethyl ether (Fisher Scienti-
fic, Pittsburgh, PA) and sacrificed by total body perfu-
sion with 4% paraformaldehyde (Fisher Scientific),
Trump’s Fixative (4% gluteraldehyde (Polysciences Inc,
Warrington, PA) + 2% paraformaldehyde), or ice cold
1× PBS, pH 7.3. Spinal cords were removed and dis-
sected into cervical, thoracic, and lumbar regions.
Trump fixed tissue was embedded in epon and one
micron thick sections were stained with toluidine blue.
For immunohistochemistry, paraformaldehyde fixed tis-
sue was immersed in 30% sucrose overnight at 4°C prior
to embedding in paraffin or OCT. Representative images
shown are WT CI = 1.5 and Axl-/- CI = 2.5, equivalent
to the average CI for each genotype at the peak of acute
phase of disease. For protein or RNA isolation, the
spinal cord was flushed out using an 18 gauge needle
and 10 cc syringe with ice cold 1× PBS. For total protein
homogenates, PBS-perfused tissue was sonicated on ice
with a tissue master 125 sonicator (Omni International,
Marietta, GA) in protein buffer (140 mM NaCl, 1 mM
Tris, pH 7.4) containing 0.5% Triton X-100 and protease
inhibitors [2 μg/mL leupeptin; 2 mM ethylene glycol-bis
(b-aminoethylether)-N,N,N’,N’-tetraacetic acid; 4 μg/mL
pepstatin; 5 mM sodium pyrophosphate; 30 mM b-gly-
cerophosphate; 30 mM sodium fluoride; 100 mM
sodium orthovanadate; 100 mM 4-(2-aminoethyl) benze-
nesulfonyl fluoride hydrochloride]. The homogenates
were cleared by centrifugation at 4°C at 7000 g for
10 min and aliquots were frozen at -80°C. For RNA
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isolation, lumbar sections of spinal cord were sonicated
in Qiazol and isolated with an RNeasy Lipid Tissue
Mini Kit (Qiagen Inc, Valencia, CA). The RNA samples
were quantified on a nanodrop ND-1000 spectrophot-
ometer (Thermo Scientific, West Palm Beach, FL) and
aliquoted at 50 ng/μl.
Western blot analysis
Eighty μg of protein was loaded in 1× final concentra-
tion loading buffer containing 2% SDS, 0.017% bromo-
phenol blue dye, and 0.28 M b-mercaptoethanol
(loading dye), and separated in a 10% SDS-PAGE [32].
Following electrophoresis, proteins were transferred to
nitrocellulose [33], and incubated with 5% non-fat dry
milk and 5% goat serum in 1× Tris buffered saline pH
7.4 (1× TBS) for 1 hr at room temperature [34]. After
blocking, membranes were incubated with respective
primary antibodies followed by HRP-conjugated second-
ary antibodies. Primary monoclonal antibodies (mAbs)
and polyclonal antibodies (pAbs) included: b-actin mAb
(IgG2A, 1:5,000; Sigma) and Axl pAb (1:1000). Second-
ary antibodies (Jackson ImmunoResearch Laboratories,
West Grove, PA) included: goat a-rabbit IgG (1:10,000),
and goat a-mouse IgG2A (1:10,000). Visualization of all
secondary antibodies was by electrochemiluminescence
(ECL) (GE Healthcare, Piscataway, NJ). Relative densito-
metric intensity (rdi) was determined for each band as
previously described [5].
Ex vivo proliferation assay
Axl-/- and WT mice were sensitized with MOG35-55 as
described above and lymphocytes were harvested from
draining lymph nodes on day 16. Single cell suspensions
were prepared and cultured in vitro with 20 μg/ml
MOG35-55 peptide. After 3 days,
3H-thymidine was
added to the cultures for an additional 48 h and assayed
for thymidine uptake using a cell harvester [35].
Quantitative RT-PCR
The Taqman RNA-to-CT 1-Step kit (Applied Biosys-
tems, Foster City, CA) was used with a total of 100 ng
of RNA per reaction with TNFa, MCP1, RANTES, and
GAPDH primers (Applied Biosystems). All results were
normalized to GAPDH as an internal control. The reac-
tions were aliquoted in triplicate in an optical 96 well-
plate; RNase-free water was used as a blank. Reactions
were run in the StepOnePlus real-time PCR machine
(Applied Biosystems) with the following cycles: hold
stage, 48°C for 15 min for reverse transcription, 95°C for
10 min to activate the DNA polymerase, followed by 40
cycles at 95°C for 15 seconds, and 60°C for 1 min. The
real-time quantification was monitored directly by the
StepOnePlus software and the comparative thresholds
(CT) were identified for each gene with each RNA
sample and calculated at the end of the measurements.
After normalization of the (CT), the fold change was
determined as fold change = 2-(ΔΔCT) where ΔΔCT is
defined as the normalized change in CT between two
groups. Statistics were performed on the normalized CT
values.
Immunohistochemistry
Paraffin-embedded and frozen sections were prepared
from the paraformaldehyde fixed tissue. Seven micron
paraffin-embedded sections were deparaffinized, rehy-
drated and then incubated for 30 min with 1× TBS con-
taining 0.25% Triton X-100 (0.01% Triton X-100 for Axl
pAb) plus 3% hydrogen peroxide, followed by a 1 hr
incubation in 5% goat serum and 5% nonfat dry milk in
1× TBS, and incubated with antibodies diluted in 5%
nonfat dry milk in 1× TBS, overnight at 4°C, with the
exception of CD45 and CD3, which were not incubated
in 0.25% Triton X-100 plus 3% hydrogen peroxide. Pri-
mary antibodies consisted of mAb to MBP (SMI99;
1:1500; Covance, Inc, Emeryville, CA), mAb CD45 (1:20;
BD Biosciences, San Jose, CA), or mAb Neurofilament
H nonphosphorylated (SMI32; 1:30,000; Covance). Ten
micron frozen sections were stained with the mAb
MAC3 (1:20; BD Pharmingen), pAb Iba1 (1:400; Wako
Chemicals, Richmond, VA) or pAb Axl (1:200; Amgen,
Thousand Oaks, CA). Control staining consisted of
omission of the primary antibody or for a polyclonal
antibody control preimmune serum was used. Sections
were washed 3× in 1× TBS and incubated with mouse
monoclonal or rabbit polyclonal secondary antibodies
followed by incubation with the appropriate Vecta stain-
ing kit (Vector Laboratories, Inc., Burlingame, CA) and
visualized by 0.3 mg/ml DAB (Sigma) in 0.1 M TRIS pH
7.4 plus 0.009% hydrogen peroxide. Quantification was
determined using an objective stage micrometer with a
reticule (Nikon, Melville, NY). Quantification of CD45
by integrated density was performed in Image J and sta-
tistical analysis was evaluated in Prism.
Immunofluorescence
Ten micron thick frozen sections were prepared from
spinal cords from 4% paraformaldehyde perfused mice.
Sections placed on Excell plus slides (Richard-Allan
Scientific, Kalamazoo, MI) were dried by placing them
at 37°C for 2 hr, or overnight at room temperature. Sec-
tions were washed in 1× TBS and blocked with 5% milk
in 1× TBS plus 5% goat serum for 1 hr at room
temperature. Double-label immunofluorescence was per-
formed sequentially. Between all primary and secondary
antibody incubation steps sections were washed 3× with
1× TBS. Primary antibody: CD3 hamster mAb (1:200,
Novus Biological, Littleton, CO) overnight at 4°C, sec-
ondary antibody: goat anti-hamster Alexa-568 (1:1000,
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Invitrogen, Carlsbad, CA) for 1 hr at room temperature,
followed by Iba1 pAb (1:400, Wako Chemicals) over-
night at 4°C, secondary antibody: goat anti-rabbit Alexa-
633 (1:1000, Invitrogen) for 1 hr at room temperature.
All antibodies were diluted in 5% milk in 1× TBS.
Hoechst stain (1:1000; Sigma), 10 min at room tempera-
ture, was used as a counterstain for nuclei. Sections
were mounted with Aquamount (Biomeda, Foster City,
CA). All samples were examined under an Olympus
(Melville, NY) 1 × 70 with a 20× numerical aperture 1.0
or a 40× numerical aperture 1.0 Plan Apo optics inverted
microscope with a Photometrics (Roper Scientific,
Tucson, AZ) Censys-cooled CCD camera; images were
collected with IPLab Spectrum software (Scanalytics,
Fairfax, VA).
Oil-Red-O staining
Frozen sections were incubated in distilled water for 1
min followed by a 2 min incubation in 100% propylene
glycol (Polyscientific, Bayshore, NY) whereupon the sec-
tions were transferred to Oil-Red-O for 36 h at room
temperature. Sections were incubated for 1 min in 85%
propylene glycol, rinsed briefly with distilled water,
lightly stained with hematoxylin and mounted with gela-
tin mounting medium.
Serum Protein Analysis
Individual serum samples from naïve wild-type (n = 6)
and Axl-/- (n = 5) mice, as well as MOG-peptide
induced EAE wild-type (n = 5) and Axl-/- (n = 9) mice,
underwent quantitative proteomic analysis for 60 che-
mokines, growth factors and cytokines as previously
described (Rules Based Medicine, Inc., Austin, TX) [36].
Briefly, sera were analyzed in a blinded fashion at a pre-
viously optimized dilution in a Luminex-based platform.
Each antigen assay was calibrated with standard curves,
performed in duplicate, and intensity measurements
were interpreted as protein concentrations within Rules
Based Medicine’s proprietary software.
CNS Preparation for Flow Cytometry and Analysis
All experimental data was acquired on an LSR II flow
cytometer (BD Biosciences). Data analysis was per-
formed using FlowJo software (Tree Star, Ashland, OR).
Following dissection of brain and spinal cord, the organs
were injected with 2 ml of RPMI1640 containing 0.3
Wünsch Units/ml Liberase TL (Roche Molecular Bio-
chemicals, Indianapolis, IN) and 10 μg/ml DNAse I
(Sigma, St. Louis, MO) and incubated at 37°C for 30
minutes. The organs were then mashed through a 70
micron cell strainer, washed twice with RPMI and cen-
trifuged at 400 × g for 10 min at 4°C. The CNS pellets
were then resuspended in 30% percoll and overlayed
onto 70% percoll, followed by centrifugation at 600 × g
for 25 min at room temperature. Cells at the interface
were collected as the CNS mononuclear cell fraction,
and analyzed by flow cytometry. Briefly, cells were
resuspended in flow cytometry buffer (PBS + 2% Fetal
Calf Serum + 0.05% NaN3) and blocked with rat anti-
mouse FcgII/III (clone 2.4G2) and stained with a cock-
tail of the following antibodies; CD4 (clone GK1.5), CD8
(clone 53-6.7), CD3e (clone 145-2C11), CD11b (clone
M1/70), CD11c (N418), Ly6G (clone 1A8) (BD Bios-
ciences), CD45 (clone 30-F11) and NKp46 (clone
29A1.4) (eBioscience, San Diego, CA) for the evaluation
of CNS infiltrating leukocyte populations. For regulatory
T cell (T regs) analysis, CNS preparations were stained
with BluVID, blocked with 2.4G2 and surface stained
with anti-CD3, anti-CD4, and anti-CD25 (clone PC-61;
BD Biosciences). Cells were then prepared for intracellu-
lar staining using a FoxP3 staining kit (eBioscience)
according to the manufacturer’s instructions and stained
with anti-FoxP3 (clone FKJ-16S) (eBioscience).
Intracellular Cytokine Staining
For analysis of cytokine producing CD4+ T cells subsets,
CNS mononuclear cells were prepared from WT and
Axl-/- mice 2 weeks following MOG induction of EAE
and re-stimulated with 10 μg/ml MOG35-55 peptide plus
1 μg/ml soluble anti-CD28 mAb (eBioscience). After
incubation (37°C, 5% CO2) for 1 h, 10 μg/ml brefeldin A
and 2 μM monensin (Sigma-Aldrich) was added for an
additional 4 h. Cells were labeled with BluVID, blocked
with mAb 2.4G2, and stained with antibodies against
CD3e, CD4, CD11b, and CD45R/B220 (clone RA3-6B2)
(BD Biosciences). Cells were fixed with 2% paraformalde-
hyde, washed with permeabilization buffer (1× PBS with
1 mM Ca2+, 1 mM Mg2+, 1 mM HEPES, 2% FCS, and
0.1% saponin), and then blocked in permeabilization buf-
fer plus 5% normal mouse serum (Jackson ImmunoRe-
search Laboratories). Intracellular cytokines were
detected with antibodies against IL-2 (clone JES6-5H4),
IL-17A (clone eBio17B7) (eBioscience), IFN-g (clone
XMG1.2), and TNFa (MP6-XT22) (BD Biosciences) [37].
Quantitative Procedures and Statistical Analysis
A student’s t-test was performed for clinical indices of WT
and Axl-/- mice derived from 3 independent experiments.
Inflammatory cuffs were quantified using a minimum of
4 sections per cord from 3 WT and 4 Axl-/- mice. For
toluidine-blue stained sections, lesions were measured
(mm2) using a reticule and a micrometer bar inserted into
the ocular of a Nikon microscope. Statistical analysis (stu-
dent t-test) was performed using mice from the same
experiment and time point. Iba1+ activated microglia were
counted in and surrounding 10 lesions in multiple sections
from WT and Axl-/- mice. SMI32+ neurofilaments were
counted in the ventral and dorsal funiculi of 3 sections per
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mouse for 3 WT and 3 Axl-/- mice. Statistical analysis was
obtained by a student’s t-test.
Results
Clinical expression of EAE in Axl-/- mice
Following sensitization with MOG peptide, Axl-/-
female mice (n = 21) had significantly higher clinical
indices than WT mice (n = 15) between days 14 and 26,
which included the acute phase and beginning of the
chronic phase of the disease (Figure 1a: 3 combined
experiments; d14, 24, 26: p < 0.05; d15-20, 22, 23: p <
0.01; d21, 25: not significant; p > 0.05). The end of the
acute phase and beginning of the chronic disease phase
occurred at day 23. There was no statistical difference
between the two treated groups prior to day 14 or dur-
ing the chronic phase of EAE, after day 26. Each of the
individual experiments showed significant differences in
the acute phase between WT and Axl-/- mice.
Concurrent experiments using TAM family member
Tyro3 knockout mice (Tyro3-/-) showed no significant
difference in clinical scores between WT and Tyro3-/-
mice during the acute or chronic phases of disease (data
not shown). Studies in other receptor tyrosine kinase
families have shown that related receptor tyrosine
kinases may be upregulated to compensate for the loss
of another receptor [38]. Thus, we examined whether
the lack of increased disease severity in Tyro3-/- was a
result of compensation by an upregulation of the Axl
receptor, using Western blot analysis of lumbar spinal
cord from naïve and MOG-sensitized WT or Tyro3-/-
mice (Figure 1b,c). In naïve WT and Tyro3-/- mice,
there was no difference in the expression of either the
immature (110 kDa) or mature form of Axl, which
migrates at 140 kDa [39]. In WT EAE mice, the 140
kDa Axl was increased 2.7-fold over naïve WT mice.
However, the 140 kDa form of Axl was increased 8-fold
in Tyro3-/- EAE mice over WT EAE mice (Figure 1c,
p = 0.02). Furthermore, there was a visible decrease in
the amount of the smaller immature form of Axl in
spinal cord homogenates from Tyro3-/- EAE mice, pre-
sumably because it was converted to the mature
140 kDa form. From these data, we conclude that acti-
vation of Axl occurs in the CNS of animals with EAE
and that upregulation of Axl in Tyro3-/- mice likely
compensates for loss of this TAM family receptor.
Analysis of peripheral immunological parameters in Axl-/-
mice sensitized for EAE
Although Axl is not expressed on T cells, to verify that
the loss of Axl did not affect the peripheral immune
response to antigen, cytokine profiles of sera from naïve
and sensitized mice were examined, using an automated
assay (see methods). No significant difference in values
for 60 different factors (see methods) was detected in
naïve or EAE-sensitized WT or Axl-/- mouse sera. In
both WT and Axl-/- mice sensitized for EAE, increased
expression over that found in naïve mice was noted for
KC/Groa, MCP-1, MMP-3, MIP1g, MIP1a, M1P1b,
MIP2, MIP3b, IL-4, IL-6, IL-7, IL-11, VEGF, LIF, OSM,
and TNFa. To explore the possibility that there was dif-
ferential activation of peripheral lymphocytes in the
Axl-/- mice during EAE lymphocytes were isolated from
draining lymph nodes on day 16 post-MOG injection.
Following activation with 20 μg/ml MOG, the fold-
increase for proliferating lymphocytes was 3.9 and 4.1
for WT and Axl-/- mice, respectively (data not shown).
Thus, there was no indication that the loss of Axl
affected the peripheral immune response to MOG in
these mice.
Analysis of immunological parameters in the CNS of
Axl-/- mice sensitized for EAE
Number and cellular-makeup of inflammatory infiltrates
consistent between Axl-/- and WT mice
To determine the cellular makeup of inflammatory infil-
trates in the CNS, flow cytometric analysis was per-
formed on cells isolated from the brains and spinal cords
of Axl-/- and WT mice sensitized for EAE (Figure 2).
The leukocyte population was identified by staining for
CD45. As shown in Figure 2, no significant difference in
the number of infiltrating leukocytes (CD4 or CD8 T
cells, NK cells, macrophages, neutrophils, microglia)
(Figure 2a), CD4+ T cell subsets (CD4+/FoxP3+ Treg,
CD25+/FoxP3-, MOG-specific IL-17A+) (Figure 2b), or
cytokine positive CD4+ T cells (IFN-g, IL-2, TNFa)
(Figure 2c) was detected.
Pro-inflammatory cytokines are upregulated in Axl-/- mice
during EAE
The experiment described above analyzed cytokine pro-
duction in T cell sub-populations. To further explore
the role of Axl in regulating cytokine production in the
spinal cord, qRT-PCR was performed. We analyzed
lumbar spinal cord at day 16 post-EAE induction to
determine whether the loss of Axl resulted in altered
pro-inflammatory cytokine and chemokine mRNA
expression compared to WT mice during acute EAE.
Since it had been reported that Axl regulates TNFa
transcription through induction of TWIST, we analyzed
TWIST expression but found no difference in the
amount of TWIST RNA between naïve and EAE-
induced Axl-/- and WT mice (data not shown). Addi-
tionally, in naïve Axl-/- and WT lumbar spinal cord
there was no difference in TNFa, MCP1, or RANTES
mRNA expression. However, as expected the pro-
inflammatory cytokines and chemokines TNFa, MCP1,
and RANTES were upregulated in the spinal cord dur-
ing acute EAE. The levels of TNFa mRNA relative to
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naïve mice in both WT and Axl-/- mice were increased
approximately 46-fold (Figure 3a). Individually, Axl-/-
mice with EAE had a 68.6-fold increase in TNFa rela-
tive to untreated Axl-/- mice and WT mice with EAE
had a 18.7-fold increase in TNFa relative to untreated
WT mice. When Axl-/- and WT mice with EAE were
grouped as severely affected (CI > 2) there was no dif-
ference in TNFa, MCP1, or RANTES mRNA. However,
in mildly-moderately affected mice with EAE (CI ≤ 2),
we found that TNFa (8.1-fold, p < 0.05), MCP1
Figure 1 Axl-/- mice have a more severe clinical course than WT mice during MOG-induced EAE. a) EAE clinical course for Axl-/- and WT
female mice. Three experiments were combined: WT (n = 15) and Axl-/- (n = 21) mice. All mice were housed in Barrier. b) Western blot analysis
was performed using an Axl pAb on 80 μg of WT naïve (untreated), WT EAE, Tyro3-/- naïve (untreated), and Tyro3-/- EAE lumbar spinal cord
homogenates. The mature Axl band migrates at 140 kDa, and the immature band (lacking post translational modifications) migrates at
approximately 110 kDa. N = 3 for all groups except WT EAE where n = 4. c) The relative densitometric intensity (rdi) was determined for each
band and normalized to b-actin. The average values for 140 kDa Axl are shown. * = p < 0.05, # = p < 0.01.
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(7.2-fold, not significant), and RANTES (11.9-fold, p <
0.05) were increased in Axl-/- lumbar spinal cord rela-
tive to WT (Figure 3b). While the increase in MCP1
was not significant, it was significant when only mildly
affected mice (CI ≤ 1.5) were grouped (12.0-fold, p <
0.05, data not shown).
Pathological analysis of the spinal cord in mice with EAE
Distribution of infiltrating lymphocytes is altered in Axl-/-
mice
To determine the effect of the loss of Axl on the patholo-
gical expression of disease, spinal cord sections were pre-
pared from WT (Figure 4a,b,c) and Axl-/- (Figure 4d,e,f)
mice during the acute phase of disease, when significant
differences in clinical indices were noted. Despite flow
cytometry data showing no difference in the number of
spinal cord leukocytes between Axl-/- and WT mice,
toluidine blue stained sections of Axl-/- spinal cords
showed marked infiltration and inflammatory cuffs. The
inflammatory cells invaginated the white matter extend-
ing toward grey matter, and were associated with myelin
loss (Figure 4 d,e,f). In contrast, toluidine blue staining of
spinal cords from WT mice showed smaller inflamma-
tory cuffs and less severe myelin loss associated with the
cuffs (Figure 4a,b,c). Quantification of the lesion sizes
showed lesions in Axl-/- mice (0.23 ± 0.017 mm2) were
Figure 2 No difference in the number of leukocytes or cytokine expression from CD4+ T cells in the CNS. Mononuclear cell preparations
from brain and spinal cord were stained for flow cytometric analysis to detect differences in the phenotype of cellular infiltrates (a). The gating
strategy allowed us to discriminate populations of microglia, macrophages, neutrophils, NK cells, CD4 and CD8 T cells (a) as well as CD4 T cell
subsets (b). CD4 T cells were restimulated with MOG35-55 peptide and analyzed for cytokine production (c). Multi-parametric flow cytometric
analysis was performed on polyfunctional CD4 T cell subsets capable of producing 3, 2, or 1 cytokine(s) simultaneously. Student’s t-test revealed
no significant differences between WT and Axl-/- mice. These data are representative of two experiments each performed in triplicate, with 4
mice/group/experiment at day 19.
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significantly larger than lesions in WT mice (0.139 ±
0.031 mm2, p = 0.03, Figure 4g).
Immunostaining was performed on lumbar and cervi-
cal sections of spinal cord, the regions of spinal cord
historically shown to be most affected by MOG-induced
EAE. To visualize the location of infiltrating leukocytes
and their correspondence to areas of demyelination,
sequential WT and Axl-/- spinal cord sections were
stained with an antibody against MBP (Figure 5a,b,g,h,i,j,
k) and CD45 (Figure 5c,d,l,m,n). CD45 staining showed
infiltrating leukocytes were distributed differently in the
WT and Axl-/- spinal cord. In WT mice, most of the
CD45+ cells were at the lateral edges of the spinal cord,
consistent with the sparsity of inflammatory cuffs seen
in the toluidine blue stained sections (Figure 5c,d). In
Axl-/- mice, infiltrating leukocytes were located in the
white matter, in inflammatory cuffs (Figure 5 l,m,n).
There was a significant increase in CD45 staining in the
lumbar spinal cord of Axl-/- mice (n = 4) relative to
WT mice (n = 3) (p = 0.01), as determined by relative
integrated density. The areas of demyelination, shown
by loss of immunoreactivity to MBP, corresponded to the
location of infiltrating CD45+ leukocytes (WT: Figure 5b,
d; Axl-/-: Figure 5j,k,m,n) confirming the results obtained
with toluidine blue staining. Spinal cord sections from
WT mice stained with an Axl antibody show that Axl
was evident in inflamed white matter (Figure 5e, higher
magnification shown in 5f). No Axl staining was seen in
EAE-induced Axl-/- mice (data not shown).
Fewer microglia/macrophages are present at lesions in
Axl-/- mice
To assess the state of activation of microglia (and
macrophages) in the spinal cord, we stained sections for
Iba1 (ionized calcium binding adaptor molecule 1). Iba1
Figure 3 Transcripts for pro-inflammatory cytokine/chemokines are increased in the lumbar spinal cord of Axl-/- mice relative to WT
during the acute phase of EAE. a) 45.7-fold increase of TNFa transcript in Axl-/- and WT lumbar spinal cord (combined) during the acute
phase of EAE relative to naïve Axl-/- and WT mice (combined); 68.8-fold increase in Axl-/- EAE mice relative to untreated Axl-/-; 18.7-fold increase
in WT EAE mice relative to WT untreated mice. b) Increased TNFa, MCP1 and RANTES transcripts were found in Axl-/- lumbar spinal cord
compared to WT. Samples of RNA from lumbar spinal cord were grouped as untreated (non-MOG EAE-induced), mice with CI’s ≤ 2, or mice with
CI’s > 2. The fold increase of pro-inflammatory cytokine/chemokines in Axl-/- lumbar spinal cord relative to WT lumbar spinal cord was
determined. Fold increase for CI ≤ 2; TNFa = 8.1, MCP1 = 7.2, RANTES = 11.9. * p < 0.05, # p < 0.001.
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is a 17 kDa EF hand protein specifically expressed in
microglia/macrophages and is upregulated during cell
activation (Figure 6). The results showed that although
the overall numbers of Iba1+ cells were the same in
Axl-/- and WT spinal cord (data not shown), there were
significantly fewer Iba1+ activated microglia and macro-
phages within and directly surrounding lesions in Axl-/-
spinal cord (24.2 ± 1.6) compared to lesions in WT
spinal cord (50.3 ± 4.7) as quantified in multiple 40×
fields (p < 0.0001; Figure 6c). To better compare the
Figure 4 Axl-/- mice have larger inflammatory cuffs and increased demyelination in the spinal cord than WT mice. One micron Trump’s
fixed cross-sections of WT (a,c,e) and Axl-/- (b,d,f) spinal cords were stained with toluidine blue. a,b) Representative 5× sections of whole spinal
cord. Two 20× sections with areas of infiltration and demyelination are shown for each 5× section (WT: c,e; Axl-/-: d,f). The 20× sections are
labeled with an asterisk (dorsal funiculus; c,d) or arrow (lateral funiculus; e,f) denoting the corresponding area on the 5× section. g) quantitative
data for the mean lesion size (mm2), see methods. Ratio of CD3+ to Iba1+ cells per lesion.
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inflammatory cells in and surrounding lesions in Axl-/-
and WT mice and to establish that the lesions in Axl-/-
mice had fewer activated microglia/macrophages relative
to lymphocytes than the lesions in WT mice, double-
label immunofluorescence was performed. Antibodies to
CD3 (T cells, green) and Iba1 (microglia/macrophages,
red) (Figure 7) were used on tissue obtained from the
most severely affected mice from each group (CI’s > 2).
As shown in Figure 7b, in Axl-/- mice, the ventral funicu-
lus, which contains the corticospinal and vestibuolspinal
Figure 5 Demyelination and infiltration of CD45+ cells in spinal cords of Axl-/- mice are enhanced relative to WT mice. Seven micron
paraffin-embedded day 14 WT and Axl-/- spinal cord sections were stained with MBP or CD45 mAb’s, and frozen sections were stained with an
Axl pAb, and were visualized by DAB. Representative images of WT (a,b) and Axl-/- (g,h,i,j,k) spinal cord stained for MBP. Arrows in a,g,i denote
areas of demyelination shown at 40× in b,h,j, respectively. Asterisks in i denote demyelinated lesions; higher magnification of one lesion at 40×
is shown in k. e,f) images of a WT mouse stained for Axl; the boxed area in e is shown at 20× in f. c,l) low magnification images of WT (c) and
Axl-/- (l) mice stained with CD45. d) serial section of b stained for CD45. Serial sections of j,k stained for CD45 are shown in m,n.
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tracts involved in motor control of the limbs and balance,
had lesions with a larger ratio of CD3+ T cells (green,
left panel merge (Figure 7a,b) and middle panel single
(Figure 7a,b)) to Iba1+ activated microglia/macrophages
(red, left panel merge (Figure 7a,b) and right panel single
(Figure 7a,b)). Furthermore, in WT mice, the microglia/
macrophages appeared to tightly encompass areas of
infiltration (Figure 7a). Similar results were found in the
lateral and dorsal funiculi; compare Figure 7c,d. Thus,
although the overall mean number of microglia and
macrophages were equivalent in the WT and Axl-/-
CNS, as determined by flow cytometry (Figure 2a), there
were fewer Iba1+ activated microglia and macrophages
within and surrounding lesions in the Axl-/- spinal cord
(Figure 7e; p = 0.01).
Axl-/- mice have more myelin debris than WT mice
Axl has also been implicated in the phagocytic activity of
macrophages. To determine if there was more myelin deb-
ris in Axl-/- mice, Oil-Red-O staining was performed to
detect the presence of lipid debris present in and around
lesions. Minimal to no Oil-Red-O+ clumps were present
in and around lesions in WT mice (Figure 8a,b); however,
there was visible clumping of Oil-Red-O+ material in and
around lesions in Axl-/- mice (Figure 8c,d). Myelin lipid
debris was present in white matter lesions of the ventral
funiculus (Figure 8a,c), lateral funiculus (Figure 8b,d), and
dorsal funiculus (data not shown). This suggested that
lipid debris from demyelinated axons were efficiently
removed from lesions in WT but not Axl-/- mice. We
hypothesized that the extensive Oil-Red-O+ material and
minimal surrounding Iba1+ microglia/macrophages dur-
ing the acute phase of EAE in Axl-/- mice may be due to a
lag in migration of these cells to sites of inflammation. To
verify that the fewer number of cells was not due to a loss
of Iba1 expression in the Axl-/- mice we studied a second
microglia/macrophage marker, MAC3. By H+E, we
selected comparable lesions from WT and Axl-/- spinal
cord to evaluate MBP, Oil-Red-O, Iba1, and MAC3 stain-
ing (Figure 8e,f,g,h,i). Again, we observed extensive Oil-
Red-O+ debris in the Axl-/- spinal cord, and minimal deb-
ris in WT mouse (arrowheads 8 g). Additionally, the Oil-
Red-O+ debris in the lumbar spinal cord of WT mice was
consistently surrounded by a concentric ring of Iba1+ and
MAC3+ inflammatory cells (Figure 8g,h,i). In WT mice
Figure 6 Axl-/- mice have significantly fewer Iba1+ microglia/macrophages within and surrounding lesions than WT mice. Ten micron
frozen WT and Axl-/- spinal cord sections were stained with an Iba1 pAb. Representative 40× images for WT (a) and Axl-/- (b) mice are shown.
The arrows point to Iba1+ microglia/macrophages and the asterisks denote lesion area. c) Iba1+ activated microglia were counted in and
surrounding multiple lesions in multiple mice for WT and Axl-/- mice. Statistical analysis was performed; student’s t-test confirmed significance
between WT and Axl-/- mice; p < 0.01.
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examined during acute disease, we observed minimal
Oil-Red-O staining (n = 9). By contrast, in the Axl-/- mice
(n = 12) the Iba1+ and MAC3+ inflammatory cells present
at the lesion site did not form a tight concentric ring and
extensive Oil-Red-O+ debris was apparent.
There is more axonal damage in Axl-/- mice
SMI32 staining of non-phosphorylated neurofilaments is
indicative of axonal damage in spinal cord white matter.
In MOG-induced EAE, SMI32 staining is associated
with lesions, and with swollen, severed or dying axons.
A comparison between WT and Axl-/- mice showed
significantly more SMI32+ axons in Axl-/- spinal cord
than in WT spinal cord, especially in the dorsal (WT:
3.9 ± 0.9; Axl-/-: 123.6 ± 22.6; p < 0.01) and ventral
(WT: 27.7 ± 6.3; Axl-/-: 90.1 ± 12.9; p < 0.05) funiculi
(Figure 9).
Thus, our data summarized in Table 1 show that rela-
tive to WT lumbar spinal cord, the focal lesions in lum-
bar spinal cord of Axl-/- mice were larger, with fewer
Iba1+ activated microglia/macrophages, a higher ratio of
CD3+ T cells to Iba1+ activated microglia/macrophages,
more Oil-Red-O+ debris, and more SMI32+ axons.
Discussion
EAE is an immune-mediated inflammatory disease of
the CNS that results in myelin and CNS cell loss, and
Figure 7 Double-label immunofluorescence confirm Axl-/- (b,d) mice have fewer Iba1+ microglia/macrophages than WT (a,c) mice in
ventral (a,b), lateral and dorsal funiculi (c,d). Ten micron frozen spinal cord sections were stained with an Iba1 pAb (red), a CD3 mAb
(green), counterstained with Hoechst stain (blue), and visualized by immunofluorescence. a,b) Left panel shows merged triple fluorescence,
middle panel shows CD3/Hoechst, and right panel shows Iba1/Hoechst for the ventral funiculus of WT (a) and Axl-/- (b) spinal cords. c,d)
Merged images of lateral and dorsal funiculi for WT and Axl-/- spinal cords. All images are 40×. e) CD3+/Iba1+ cells/lesion for WT and Axl-/-
mice.
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axonal damage. In this study, we used the MOG-
induced mouse model of EAE to determine the contri-
bution of Axl to inflammation in the CNS, including
assessment of the role of Axl in cytokine/chemokine
expression, microglia/macrophage migration and the effi-
ciency with which these cells clear tissue debris. Based on
the multiple functions of Axl pertinent to protection
against EAE, results from our previous cuprizone study
[15], and current data that showed Axl is upregulated in
EAE, we predicted that Axl-/- mice would have a more
severe clinical disease course and more severe pathology
than WT mice. Consistent with this prediction, the
results showed that although the day of disease onset was
the same for Axl-/- and WT mice, Axl-/- mice had
higher clinical indices at 14 days post-MOG-injection
and that increased disease severity persisted in Axl-/-
mice throughout the acute phase. In contrast to Axl-/-
mice, the clinical course of MOG-induced EAE in
Figure 8 Axl-/- mice do not clear myelin debris as efficiently as WT mice. Ten micron frozen WT and Axl-/- spinal cord sections were
stained with the lipid dye Oil-Red-O (a,b,c,d,g). Myelin debris appears as dense red clumps. Arrowheads in g show sparse Oil-Red-O+ deposits in
the WT lesion. Representative 10× (a,b,c,d left panel) and corresponding 40× (a,b,c,d right panel) images are shown for the ventral (a,c) and
lateral (b,d) funiculi of WT (a,b) and Axl-/- mice (c,d, e,f,g,h,i) 40× images of sections showing H+E (e), MBP (f), Iba1 (h) and MAC3 (i) for WT and
Axl-/- mice.
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Tyro3-/- and WT mice was the same, perhaps reflecting
the upregulation of the mature 140 kDa form of Axl that
compensated for the lack of Tyro3.
The acute phase of the disease is attributed to break-
down of the BBB, edema, and influx of inflammatory
cells, resulting in myelin loss, and axonal damage in the
spinal cord. The detection of higher clinical scores in
the Axl-/- mice predicted there would be more damage
in the spinal cord of Axl-/- mice than WT mice. As pre-
dicted, relative to WT mice the loss of Axl resulted in
Figure 9 The spinal cord of Axl-/- mice has more axonal damage in the ventral and dorsal funiculi than WT mice. Seven micron
paraffin-embedded WT and Axl-/- spinal cord sections were stained with SMI32, a mAb for non-phosphorylated neurofilaments. Representative
20× images are shown for the ventral and dorsal funiculi of WT and Axl-/- mice. b) SMI32+ non-phosphorylated neurofilament deposits were
counted in the ventral and dorsal funiculi of three WT and three Axl-/- mice. Three or four sections were counted for each mouse and averaged.
A student’s t-test was performed to test significance; * = p < 0.05, # = p < 0.01.
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larger inflammatory cuffs comprised of CD45 and CD3
stained leukocytes but fewer lesion-associated Iba1+
microglia/macrophages. Spinal cord lesions in Axl-/-
mice also displayed increased loss of myelin, increased
accumulation of myelin debris, and significantly more
SMI32+ axons. This increased axonal damage likely
reflects increased loss of myelin, which renders axons
more vulnerable to damage and axonal die-back [40,41].
The severity of disease is mediated at least in part by
the increase in pro-inflammatory cytokines and chemo-
kines. For example, an increase in TNFa can lead to
increased vascular permeability and expression of che-
moattractant cytokines, such as MCP1 and RANTES,
which together could result in greater tissue damage in
the Axl-/- spinal cord [42-44]. Previous studies have
shown that RANTES is activated at the onset of EAE
and that expression correlates with leukocyte accumula-
tion in the CNS [45]. Activated astrocytes and cells of
monocyte/macrophage lineage secrete MCP1, which
binds to its ligand CCR2 to recruit other monocytes/
macrophages to areas of damage. Naïve mice had very
low levels of TNFa, MCP1, and RANTES mRNA and
there was no difference in the lumbar spinal cord
between Axl-/- and WT mice. However, during EAE,
mRNA for these cytokines and chemokines were upre-
gulated in the spinal cord with levels corresponding to
the severity of disease. Flow cytometric analysis deter-
mined there was no difference in TNFa expression by
infiltrating T cells in the brain and spinal cord between
Axl-/- and WT mice. Therefore, the observed differ-
ences in TNFa mRNA in the lumbar spinal cord can
likely be attributed to macrophages and/or resident CNS
cells. Differences in cytokine expression in Axl-/- mice
versus WT mice were most obvious in mice with lower
CI’s. At CI’s ≤ 2 there was significantly more mRNA for
TNFa and RANTES in the spinal cord of Axl-/- mice.
At CI’s > 2 no difference in the ratio of TNFa, MCP1,
and RANTES transcripts was detected suggesting that
the cell machinery was maximally producing these tran-
scripts. Despite the increase in MCP1 transcripts in
Axl-/- spinal cord during EAE, Iba1+ microglia/macro-
phages were under-represented in lesions relative to
spinal cord lesions of WT mice. This may reflect a role
for Axl in cell migration.
The most striking difference in spinal cord pathology
between Axl-/- mice and WT mice was noted in the
distribution of activated microglia associated with
lesions and the lack of clearance of Oil-Red-O+ debris.
Normally, resting microglia are evenly distributed
throughout the gray and white matter of the spinal cord
where they are thought to function as monitors of tissue
damage and the influx of foreign material [46]. Once
damage or a foreign antigen is detected microglia
become activated and migrate to affected areas of the
CNS [47]. Several studies have implicated a role for Axl
signaling in cell migration. In studies of gliomas, domi-
nant-negative Axl lacking the intracellular domain inter-
fered with cell migration [48], and in GN11 cells Gas6
signaling downstream of Axl was implicated in cell
migration [49]. We observed that although there was no
difference in the number of microglia in the brain and
spinal cord of mice with EAE, Axl-/- mice failed to dis-
play equivalent numbers of activated microglia/macro-
phages surrounding lesioned areas of the spinal cord
when compared with WT counterparts. Furthermore,
the microglia/macrophages recruited to lesioned areas of
the cord in the WT mice appeared to form concentric
rings around the lesions, suggesting that these cells
acted to cordon off the damaged tissue. Failure to do
this in the Axl-/- mice could account for the increase in
lesion size noted in these mice. Failure to efficiently
recruit phagocytic microglia has also been implicated in
the reduced capacity of older animals to effectively
remyelinate (reviewed in [25,50]). The additional Oil-
Red-O+ debris associated with lesions in Axl-/- relative
to lesions in WT mice is indicative of the persistence of
myelin debris not cleared by Iba1+ or Mac3+ inflamma-
tory cells. Several possibilities might account for the
persistent Oil-Red-O+ debris including the increased
clinical severity and higher scores observed in the Axl-/-
mice resulting in extensive demyelination, the inability of
the Axl-/- microglia/macrophages to efficiently migrate
to the site of injury and/or inefficient uptake of the Oil-
Red-O+ myelin debris by the inflammatory cells. In colla-
boration with the laboratory of Dr. Dianne Cox at Albert
Einstein College of Medicine, in vitro uptake assays were
performed to determine whether macrophages isolated
from WT and Axl-/- mice efficiently engulfed debris.
Qualitatively, there was no difference in FcgR-mediated
or CR3-mediated phagocytosis as determined by equiva-
lent uptake of IgG-coated erythrocytes or zymosan parti-
cles, respectively, in WT and Axl-/- macrophages (data
not shown) indicating that macrophages from Axl-/-mice
were capable of efficient engulfment.
Table 1 Summary of clinical and pathological data for
the acute phase of EAE in WT and Axl-/- mice
WT Axl-/-
Average size of lesions (p < 0.01) 0.13 ± 0.03 0.23 ± 0.02
Iba1+ microglia/macrophages per lesion
(p < 0.01)
50.3 ± 4.7 24.2 ± 1.6
Ratio of CD3+ to Iba1+ cells per lesion
(p < 0.01)
1.3 ± 0.07 3.7 ± 0.26
Extent of Oil-Red-O+ debris per lesion
(p < 0.01)
+ +++
Mean number SMI32+ axons
Ventral lumbar spinal cord (p < 0.05) 27.7 ± 6.3 90.1 ± 12.6
Dorsal lumbar spinal cord (p < 0.01) 3.9 ± 0.9 123.6 ± 22.6
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In most animal models of CNS demyelination, elimi-
nation of myelin debris is a necessary prerequisite for
remyelination and repair. In young animals this is
accomplished efficiently by phagocytic macrophages and
microglia (reviewed in [50]). Axl, Tyro3 and Mer have
all been shown to be required for efficient phagocytosis
of apoptotic cells [30]. Also, it is possible for myelin
debris to persist in the lesion area as shown by extracy-
toplasmic Oil-Red-O staining observed in pathologic
and necrotic tissue, a condition present in EAE lesions
[51-53]. Thus, increased Oil-Red-O+ debris in Axl-/-
mice during EAE likely reflects a failure of Iba1+ and/or
MAC3+ inflammatory cells to efficiently migrate to the
injury site in order to clear debris, leading to impaired
remyelination and tissue damage.
Conclusions
Taken together, these data support the conclusion
that exacerbation of acute EAE in Axl-/- mice reflects
the role of Axl in regulating the activity of cells of the
monocyte/macrophage series, whilst having little
effect on the activity of lymphocytes. This would be
consistent with the known distribution of Axl, and
other TAM receptors, which are constitutively but
variably expressed by all subpopulations of mono-
cytes/macrophages, but are not expressed by most
mature lymphocytes (reviewed in [54]). The data show
that Axl is important for several aspects of tissue
homeostasis in the spinal cord of mice with EAE
including migration of macrophages/microglia to sites
of tissue damage, the efficient walling off of the lesion
and the clearance of tissue debris that in turn likely
limits the extent of damage. These findings have sig-
nificant relevance for our understanding of the patho-
genesis of MS. Our previous work has shown that Axl
and a deleterious soluble form of Axl are upregulated
in MS lesions, and that the soluble form of Axl nega-
tively correlates with expression of the TAM receptor
ligand Gas6 [5]. The data further suggest that increas-
ing the availability of Gas6 in MS lesions may lead to
enhanced Axl activation resulting in the arrest of
lesion enlargement thus favoring remyelination and
repair of tissue damage.
Acknowledgements
This study was funded by the National Multiple Sclerosis Society (NMSS)
Research Grants RG3020 (BSZ) and RG4046 (BSZ), National Institutes of
Health (NIH) grant NINDS 1R21NS061128-01A1 (BSZ), the Training Program
in Cellular and Molecular Biology and Genetics grant, NIH NIGMS GM07491
(JGW). We thank Dr. Phyllis Novikoff for her help with the Oil-Red-O staining.
We thank Dr. Greg Lemke and Dr. Qingxian Lu at the Salk Institute for
Biological Studies for receipt of the Axl-/- and Tyro3-/- mice. We are grateful
to Dr. Laura Santambrogio at Albert Einstein College of Medicine for her
constructive comments and stimulating discussions. We thank Christina Liu
at Albert Einstein College of Medicine for help with qRT-PCR.
Author details
1Department of Pathology, Albert Einstein College of Medicine, 1300 Morris
Park Avenue, Bronx, New York 10461, USA. 2Department of Epidemiology &
Population Health, Albert Einstein College of Medicine, 1300 Morris Park
Avenue, Bronx, New York 10461, USA. 3Department of Microbiology &
Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
4Department of Inflammation, Amgen Inc., 1201 Amgen Court West, Seattle,
WA 98119, USA. 5Department of Psychological and Brain Sciences, Indiana
University, 1101 East 10th Street, Bloomington, IN 47405, USA.
Authors’ contributions
JGW, CFB, VT and BSZ induced EAE in the mice. JGW and BSZ performed
protein isolation and analysis (Western blot), immunohistochemistry, and Oil-
Red-O staining. JGW and OL isolated RNA and performed quantitative PCR.
MFG and FM did CNS preparations and isolated inflammatory cells for flow
cytometry and analysis. MFG performed intracellular cytokine staining. The ex
vivo proliferation assay was performed by CFB and BSZ. HAA performed the
serum protein analysis. ALP supplied the Axl polyclonal antibody. All authors
have read and approved the final version of the manuscript.
Competing interests
The funding agency had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript. The authors
have no financial or non-financial competing interests to declare.
Received: 22 December 2010 Accepted: 15 May 2011
Published: 15 May 2011
References
1. Camenisch TD, Koller BH, Earp HS, Matsushima GK: A novel receptor
tyrosine kinase, Mer, inhibits TNF-alpha production and
lipopolysaccharide-induced endotoxic shock. J Immunol 1999,
162:3498-3503.
2. Lu Q, Lemke G: Homeostatic regulation of the immune system by
receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293:306-311.
3. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS,
Matsushima GK: Phagocytosis and clearance of apoptotic cells is
mediated by MER. Nature 2001, 411:207-211.
4. Binder MD, Cate HS, Prieto AL, Kemper D, Butzkueven H, Gresle MM,
Cipriani T, Jokubaitis VG, Carmeliet P, Kilpatrick TJ: Gas6 deficiency
increases oligodendrocyte loss and microglial activation in response to
cuprizone-induced demyelination. J Neurosci 2008, 28:5195-5206.
5. Weinger JG, Omari KM, Marsden K, Raine CS, Shafit-Zagardo B: Up-
regulation of soluble Axl and Mer receptor tyrosine kinases negatively
correlates with Gas6 in established multiple sclerosis lesions. Am J Pathol
2009, 175:283-293.
6. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S,
Ambros PF, Bartram CR: A novel putative tyrosine kinase receptor with
oncogenic potential. Oncogene 1991, 6:2113-2120.
7. O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C,
Espinosa R, Le Beau MM, Earp HS, Liu ET: axl, a transforming gene isolated
from primary human myeloid leukemia cells, encodes a novel receptor
tyrosine kinase. Mol Cell Biol 1991, 11:5016-5031.
8. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS: Cloning and
mRNA expression analysis of a novel human protooncogene, c-mer. Cell
Growth Differ 1994, 5:647-657.
9. Jia R, Hanafusa H: The proto-oncogene of v-eyk (v-ryk) is a novel
receptor-type protein tyrosine kinase with extracellular Ig/GN-III
domains. J Biol Chem 1994, 269:1839-1844.
10. Funakoshi H, Yonemasu T, Nakano T, Matumoto K, Nakamura T:
Identification of Gas6, a putative ligand for Sky and Axl receptor
tyrosine kinases, as a novel neurotrophic factor for hippocampal
neurons. J Neurosci Res 2002, 68:150-160.
11. Shankar SL, O’Guin K, Cammer M, McMorris FA, Stitt TN, Basch RS, Varnum B,
Shafit-Zagardo B: The growth arrest-specific gene product Gas6 promotes
the survival of human oligodendrocytes via a phosphatidylinositol 3-
kinase-dependent pathway. J Neurosci 2003, 23:4208-4218.
12. Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Puta E, Naldi P,
Castello L, Monaco F, Avanzi GC: Elevation of Gas6 protein concentration
in cerebrospinal fluid of patients with chronic inflammatory
Weinger et al. Journal of Neuroinflammation 2011, 8:49
http://www.jneuroinflammation.com/content/8/1/49
Page 16 of 18
demyelinating polyneuropathy (CIDP). J Neurol Sci 2008, 269:138-142.
13. Manfioletti G, Brancolini C, Avanzi G, Schneider C: The protein encoded by
a growth arrest-specific gene (gas6) is a new member of the vitamin K-
dependent proteins related to protein S, a negative coregulator in the
blood coagulation cascade. Mol Cell Biol 1993, 13:4976-4985.
14. Prieto AL, Weber JL, Tracy S, Heeb MJ, Lai C: Gas6, a ligand for the
receptor protein-tyrosine kinase Tyro-3, is widely expressed in the
central nervous system. Brain Res 1999, 816:646-661.
15. Hoehn HJ, Kress Y, Sohn A, Brosnan CF, Bourdon S, Shafit-Zagardo B: Axl-/-
mice have delayed recovery and prolonged axonal damage following
cuprizone toxicity. Brain Res 2008, 1240:1-11.
16. Heide I, Sokoll AC, Henz BM, Nagel S, Kreissig K, Grutzkau A, Grabbe J,
Wittig B, Neubauer A: Regulation and possible function of axl expression
in immature human mast cells. Ann Hematol 1998, 77:199-205.
17. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB:
Twist mediates suppression of inflammation by type I IFNs and Axl. J
Exp Med 2006, 203:1891-1901.
18. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, De
Groot CJ: Expression of MCP-1 by reactive astrocytes in demyelinating
multiple sclerosis lesions. Am J Pathol 1999, 154:45-51.
19. Cannella B, Raine CS: The adhesion molecule and cytokine profile of
multiple sclerosis lesions. Ann Neurol 1995, 37:424-435.
20. Hofman FM, Hinton DR, Johnson K, Merrill JE: Tumor necrosis factor
identified in multiple sclerosis brain. J Exp Med 1989, 170:607-612.
21. Selmaj K, Raine CS, Cannella B, Brosnan CF: Identification of lymphotoxin
and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991,
87:949-954.
22. dos Santos AC, Barsante MM, Arantes RM, Bernard CC, Teixeira MM,
Carvalho-Tavares J: CCL2 and CCL5 mediate leukocyte adhesion in
experimental autoimmune encephalomyelitis–an intravital microscopy
study. J Neuroimmunol 2005, 162:122-129.
23. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W,
Helwig A, Poser S: Tumor necrosis factor-alpha messenger RNA
expression in patients with relapsing-remitting multiple sclerosis is
associated with disease activity. Ann Neurol 1995, 37:82-88.
24. Tanuma N, Abe S, Shin T, Kojima T, Ishihara Y, Arai Y, Toyoshima S,
Matsumoto Y: Pretreatment with T cell receptor peptides using a
conventional immunization protocol does not induce effective
protection against autoimmune encephalomyelitis. Cell Immunol 1996,
168:85-90.
25. Neumann H, Kotter MR, Franklin RJ: Debris clearance by microglia: an
essential link between degeneration and regeneration. Brain 2009,
132:288-295.
26. Rappert A, Bechmann I, Pivneva T, Mahlo J, Biber K, Nolte C, Kovac AD,
Gerard C, Boddeke HW, Nitsch R, Kettenmann H: CXCR3-dependent
microglial recruitment is essential for dendrite loss after brain lesion. J
Neurosci 2004, 24:8500-8509.
27. Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL: Role of microglia
in the central nervous system’s immune response. Neurol Res 2005,
27:685-691.
28. Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector
cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
29. Heneka MT, O’Banion MK, Terwel D, Kummer MP: Neuroinflammatory
processes in Alzheimer’s disease. J Neural Transm 2010, 117:919-947.
30. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK: Macrophages
and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance
of apoptotic cells. J Immunol 2007, 178:5635-5642.
31. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del
Carro U, Amadio S, Bergami A, Furlan R, Comi G, Cescovi AL, Martino G:
Injection of adult neurospheres induces recovery in a chronic model of
multiple sclerosis. Nature 2003, 422:688-694.
32. Laemmli UK: Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970, 227:680-685.
33. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
34. Zamora-Leon SP, Bresnick A, Backer JM, Shafit-Zagardo B: Fyn
phosphorylates human MAP-2c on tyrosine 67. J Biol Chem 2005,
280:1962-1970.
35. Chen L, Brosnan CF: Exacerbation of experimental autoimmune
encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic
activity in lymphocytes. J Immunol 2006, 176:3115-3126.
36. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP,
Mansfield BC: Multianalyte profiling of serum antigens and autoimmune
and infectious disease molecules to identify biomarkers dysregulated in
epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008,
17:2872-2881.
37. Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, Chan J,
Reddington F, Besra GS, Jacobs WR Jr, Porcelli SA: Incorporation of NKT
cell-activating glycolipids enhances immunogenicity and vaccine
efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol
2009, 183:1644-1656.
38. Mueller KL, Hunter LA, Ethier SP, Boerner JL: Met and c-Src cooperate to
compensate for loss of epidermal growth factor receptor kinase activity
in breast cancer cells. Cancer Res 2008, 68:3314-3322.
39. O’Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET: The transforming
receptor tyrosine kinase, Axl, is post-translationally regulated by
proteolytic cleavage. J Biol Chem 1995, 270:551-557.
40. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W: Acute axonal
damage in multiple sclerosis is most extensive in early disease stages
and decreases over time. Brain 2002, 125:2202-2212.
41. Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, Trapp BD:
Axon loss in the spinal cord determines permanent neurological
disability in an animal model of multiple sclerosis. J Neuropathol Exp
Neurol 2002, 61:23-32.
42. Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME,
Corti A: Roles of tumor necrosis factor p55 and p75 receptors in TNF-
alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001, 281:
C1173-1179.
43. Wolf G, Aberle S, Thaiss F, Nelson PJ, Krensky AM, Neilson EG, Stahl RA: TNF
alpha induces expression of the chemoattractant cytokine RANTES in
cultured mouse mesangial cells. Kidney Int 1993, 44:795-804.
44. Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, Hsieh BS: Dual regulation of
tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant
protein-1 expression in vascular smooth muscle cells by nuclear factor-
kappaB and activator protein-1: modulation by type III
phosphodiesterase inhibition. J Pharmacol Exp Ther 2004, 309:978-986.
45. Glabinski AR, Tuohy VK, Ransohoff RM: Expression of chemokines RANTES,
MIP-1alpha and GRO-alpha correlates with inflammation in acute
experimental autoimmune encephalomyelitis. Neuroimmunomodulation
1998, 5:166-171.
46. Kreutzberg GW: Microglia, the first line of defence in brain pathologies.
Arzneimittelforschung 1995, 45:357-360.
47. Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: intrinsic
immuneffector cell of the brain. Brain Res Brain Res Rev 1995, 20:269-287.
48. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-
Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, Erber R, Ullrich A:
Dominant-negative inhibition of the Axl receptor tyrosine kinase
suppresses brain tumor cell growth and invasion and prolongs survival.
Proc Natl Acad Sci USA 2006, 103:5799-5804.
49. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, Varnum B, Kandel ER,
Heidenreich KA, Wierman ME: Novel mechanism for gonadotropin-
releasing hormone neuronal migration involving Gas6/Ark signaling to
p38 mitogen-activated protein kinase. Mol Cell Biol 2002, 22:599-613.
50. Franklin RJ, Kotter MR: The biology of CNS remyelination: the key to
therapeutic advances. J Neurol 2008, 255(Suppl 1):19-25.
51. Rémy C, Fouilhé N, Barba I, Sam-Lai E, Lahrech H, Cucurella MG,
Izquierdo M, Moreno A, Ziegler A, Massarelli R, Décorps M, Arús C: Evidence
that mobile lipids detected in rat brain glioma by 1H nuclear magnetic
resonance correspond to lipid droplets. Cancer Res 1997, 57:407-414.
52. Lahrech H, Zoula S, Farion R, Rémy C, Décorps M: In vivo measurement of
the size of lipid droplets in an intracerebral glioma in the rat. Magn
Reson Med 2001, 45:409-414.
53. Rizk T, Montero-Menei C, Jollivet C, Benoit JP, Menei P: Pitfalls in the
detection of lipid vectors in neural cell culture and in brain tissue. J
Biomed Mater Res A 2004, 68:360-364.
54. Lemke G, Rothlin CV: Immunobiology of the TAM receptors. Nat Rev
Immunol 2008, 8:327-336.
Weinger et al. Journal of Neuroinflammation 2011, 8:49
http://www.jneuroinflammation.com/content/8/1/49
Page 17 of 18
doi:10.1186/1742-2094-8-49
Cite this article as: Weinger et al.: Loss of the receptor tyrosine kinase
Axl leads to enhanced inflammation in the CNS and delayed removal of
myelin debris during Experimental Autoimmune Encephalomyelitis.
Journal of Neuroinflammation 2011 8:49.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Weinger et al. Journal of Neuroinflammation 2011, 8:49
http://www.jneuroinflammation.com/content/8/1/49
Page 18 of 18
